David H. Williams

发表

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Gary Box, Ian Collins, Melanie Valenti, 2010, Molecular Cancer Therapeutics.

Molecular Cancer Therapeutics The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK 1 Inhibitor SAR-020106

M. Walton, K. Boxall, G. Aherne, 2009 .

Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates.

David H. Williams, T. Mitchell, 2002, Current opinion in pharmacology.

Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.

Clive S Mason, P. Eyers, M. Lamers, 2010, ACS chemical biology.

Discovery and Exploitation of Inhibitor-resistant Aurora and Polo Kinase Mutants for the Analysis of Mitotic Networks◆

P. Eyers, M. Chu, C. Bignell, 2009, The Journal of Biological Chemistry.

Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes.

L. Tabernero, P. Eyers, M. Chu, 2010, Biochemistry.

Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing

Gary Box, Ian Collins, Isaac M. Westwood, 2011, Journal of medicinal chemistry.

Structure of a Cys25-->Ser mutant of human cathepsin S.

M. Lamers, R. Hubbard, A. Brzozowski, 2002, Acta crystallographica. Section D, Biological crystallography.

Identification of inhibitors of checkpoint kinase 1 through template screening.

Ian Collins, Samantha Burns, David Williams, 2009, Journal of medicinal chemistry.

Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine.

M. Lamers, A. Antson, R. Hubbard, 1999, Journal of molecular biology.